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1. Introduction
AS is a disease accompanied by an autoimmune re-
sponse to low-density lipoprotein (LDL) that causes 
strokes, ischemic heart diseases, and peripheral vascular 
diseases etc., which has been one of the most usual chron-
ic fatal causes in aged people. Early diagnosis, prevention, 
and further accumulation inhibition of atherosclerotic 
plaque have become the main directions of cardiovascular 
disease research. 
In the medical imaging evaluation of atherosclerotic 
lesions, medical imaging apparatus such as ultrasound, 
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Atherosclerosis (AS) is a primary cause of morbidity and mortality all over 
the world. Molecular imaging techniques can enable early localization 
and diagnosis of atherosclerosis plaques. Recent newly developed 
chitooligosaccharides (CSO) is considered to be capable of target mannose 
receptors on the surface of macrophages and to inhibit foam cell formation. 
Here we present a targeting magnetic resonance imaging (MRI) nanoprobe, 
which was successfully constructed with polyacrylic acid (PAA) modified 
nanometer iron oxide (Fe3O4) as the core, and coating with CSO molecules, 
possessing the abilities of targeted MRI and specifically inhibition of 
the formation of foamy macrophages in the atherosclerotic process. The 
experimental results showed that the distributions of PAA-Fe3O4 and CSO-
PAA-Fe3O4 were uniform and the corresponding sizes were about 5.93 
nm and 8.15 nm, respectively. The Fourier transform infrared spectra 
(FTIR) testified the CSO was coupled with PAA-Fe3O4 successfully. After 
coupled with CSO, the r1 of PAA-Fe3O4 was increased from 5.317 mM s
-1 
to 6.147 mM s-1, indicating their potential as MRI contrast agent. Oil Red 
O staining and total cholesterols (TC) determination showed that CSO-
PAA-Fe3O4 could significantly inhibit the foaming process of RAW264.7 
cells induced by oxidatively modified low density lipoprotein (ox-LDL). 
In vitro cellular MRI displayed that, compared with PAA-Fe3O4,CSO-
PAA-Fe3O4 could lower the T1 relaxation time of RAW264.7 cells better. 
In summary, construction of CSO-PAA-Fe3O4 nanoprobe in this study 
could realize the targeted MRI of macrophages and inhibition of ox-LDL 
induced macrophage foaming process. This will provide a new avenue in 
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MRI, computerized tomography (CT), and nuclear medicine 
have made remarkable breakthroughs over time [1-4]. Among 
them, MRI as a non-invasive diagnosis mode has been 
well applied to analyze the degree of stenosis, vessel wall 
thickness, and plaque size. It should be mentioned that 
although MRI has sufficient spatial resolution and good 
signal-to-noise ratio, however, it is not specific enough to 
characterize the composition of atherosclerotic plaques [5]. 
Therefore, application of MR for the assessment of AS, 
especially at an early stage, has significant limitations. 
In recent years, the rapid development of molecular MRI 
nanoprobe has become an essential tool for studying AS 
under its advantages [6], including non-invasive, radia-
tion-free, multiplanar imaging, multi-serial imaging, and 
high soft-tissue resolution, providing a new approach for 
the early detection of AS plaques [7]. 
Iron oxide as MRI contrast agent coupling with the tar-
geting molecules has been used in vascular imaging, mac-
rophage uptake, cell labeling, and cancer hyperthermia [8-12]. 
Since common iron oxide nanoparticles are easily phago-
cytosed by peripheral phagocytes during circulation due 
to physical properties as well as biological characteristics, 
which may weaken their imaging performance. In order 
to enhance the biological compatibility and evade particle 
agglomerations, polymers, little molecules, surfactants, and 
others are commonly used to clad nanoparticles. Iron oxide 
magnetic nanoparticles have been employed as T2 contrast 
medium, giving a negative comparison diagram in the or-
dinary way. In clinically, T2-weighted images (T2WI) were 
used to examine organ pathological changes, but these were 
more prone to motion artifact from longer acquisition times. 
T2WI needs a longer repetition time (TR) and echo time 
(TE) than T1-weighted images (T1WI) as well as clearer T2 
images require more advanced MRI equipment, which all 
greatly increase the cost of clinical examination. Based on 
the presence of a high-intensity signal within the embolus 
or intraplaque hemorrhage caused by methemoglobin T1 
shortening, the plaque characterization with T1WI in MR has 
facile plaque imaging [13]. With the function of their sizes, 
superparamagnetic iron oxide nanoparticles (SPIO NPs) may 
provide a positive contrast in T1WI 
[14]. At the same time, it is 
different from gadolinium-containing contrast agents, which 
are cytotoxic and tend to accumulate in tissues organs. Iron 
oxide nanoparticles provide a safer gadolinium-free T1 con-
trast agent for MR imaging [15]. In this work, we synthesized 
PAA modified SPIO NPs as T1 MRI contrast agent.
Macrophages have been the most extensively studied 
target to study AS plaques. Numerous studies have shown 
that macrophages were involved in the process of AS 
development and were closely related to plaque stability, 
playing an essential regulatory role in the atherosclerotic 
pathological process [16]. In the early stage of the disease, 
inflammatory cells such as monocytes and macrophages 
enter the damaged blood vessel wall under the chemot-
actic action of various inflammatory factors and phago-
cytize lipids to become foam cells. In the late stage of the 
disease, macrophages, foam cells, lymphocytes, and mast 
cells are the main components of AS plaques, with mac-
rophages and lymphocytes being the main cellular com-
ponents in ruptured plaques. CSO are oligomers of chi-
tosan and consist of 3 to 10 units of N-acetylglucosamine 
or glucosamine. The CSO has been reported to interact 
with mannose receptors on the surface of macrophages 
through N-acetylglucosamine structures [17]. The mannose 
receptors on macrophages are consisted of extracellular 
cysteine-rich region (CR), type II fibronectin region (FN 
II), and C-type lectin-like region (CTLD). Especially, 
in the CTLD chains of extracellular mannose receptor, 
CTLD4 can recognize and bind the N-acetylglucosamine 
residues of CSO in CTLD1 - 8. At the same time, with 
the synergistic participation of CTLD5-8, mannose re-
ceptors can bind to ligands more closely and firmly [18]. 
Miraculously, CSO binding to macrophages significantly 
enhanced the abundant adenosine triphosphate-binding 
cassette transporter A1 (ABCA1) on the surface of mac-
rophages, mediating cholesterol efflux out of the cell, and 
reversing the transport of cholesterol mediated by ABCA1 
bound to Apolipoprotein A1 (ApoA1) and high-density 
lipoprotein (HDL), resulting in a significant decrease in 
intracellular cholesterol levels. It has also been found 
that CSO promotes intracellular cholesterol efflux while 
increasing the level of macrophage autophagy and further 
inhibiting macrophage frothing [19,20]. Besides retaining the 
excellent biocompatibility and non-biotoxicity of chitosan, 
CSO keeps better water solubility and extral biological 
activities, including antibacterial, antifungal, antiviral, 
anti-tumor, exert fat, blood pressure control and hypo-
cholesteromic effects [21], which have been widely used in 
antitumor and antioxidant applications [22,23]. Meanwhile, 
CSO nanoparticles possess lower haemolysin activity, cy-
toxicity and the high encapsulation efficiency made them 
as an effective carrier [24]. Thus, CSO is expected to be 
used as the targeting molecule and therapy drug for AS.
In this report, we simply conjugated PAA modified Fe3O4 
nanoparticles (PAA-Fe3O4) with CSO to fabricate the ther-
anostic nanoprobe for AS. Such conjugation was realized 
via amide bonds between carboxyl groups on the surface 
of PAA-Fe3O4 and amino groups of CSO (Figure 1a). CSO 
not only directs PAA-Fe3O4 to bind smoothly to the foaming 
macrophages via mannose receptors (Figure 1b) and achieves 
enhanced MR imaging by endocytosis (Figure 1c), but also 
effectively inhibits the further development of macrophages 
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toward foam cells by promoting the out-cell transport of ac-
cumulated lipids within the macrophages and reducing the 
cholesterol content of the cells. The introduction of a CSO 
coating on the surface of iron oxide nanoparticles will greatly 
increase biocompatibility, thus facilitating the biomedical ap-
plication of these nanoparticles and providing new ideas for 
the diagnosis and treatment of AS.
2.	Materials	and	Methods
Materials
PAA was purchased from Aladdin Co., Ltd (Shang-
hai, China). Ferric chloride·Hexahydrate (FeCl3·6H2O) 
was acquired from Wokai Biotech Co., Ltd (Shandong, 
China). Ferrous sulfate·Heptahydrate (FeSO4·7H2O) was 
purchased from Meilunbio Co., Ltd (Shanghai, China). 
Both 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) were obtained 
from Sigma-Aldrich (America). CSO (average molecular 
weight <1000) was ordered from Dibai Biotech Co., Ltd 
(Shanghai, China). RPMI1640 medium was got from 
Keygen Biotech Co., Ltd (Jiangsu, China). Ox-LDL was 
collected from Yuanye Biotechnology Co., Ltd (Beijing, 
China). The whole cholesterol detection kit was acquired 
from Suoqiao Biotech Co., Ltd (Beijing, China). Mouse 
mononuclear macrophage leukemia cells (RAW264.7) 
were obtained from the Cell Bank of the Chinese Acade-
my of Sciences (Shanghai, China).
Synthesis	of	PAA	modified	Fe3O4 nanoparticles
The synthetic approach for PAA-Fe3O4 was referred to 
a literature previously reported by Kucheryavy et al. [25]. 
Briefly, a 20 mL amount of 4 mg/mL PAA solution was 
Figure	1. Schematic illustration of the synthesis route of CSO-PAA-Fe3O4 nanoprobe (a). The mannose receptor on 
macrophage surface is composed of CR, FN II and CTLDs. Among them, CTLD4-8 can specifically recognize and bind 
the N-acetylglucosamine residue of CSO, (b). Endocytosis of CSO-PAA-Fe3O4 by macrophages (c).
DOI: https://doi.org/10.30564/jams.v4i2.3039
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first to remove oxygen by purgeding (≥50 min)with nitro-
genand was heated to 100℃ with a magnetic stirrer. After 
that, 0.4 mL of FeCl3 & FeSO4 solution (1.0 mol/L FeCl3 
and 0.5 mol/L FeSO4) was quickly injected, followed by 
the addition of 9.0 mL of 28% ammonia solution. After 
stirred for 15 minutes, 0.6 mL of the FeCl3 & FeSO4 solu-
tion and 4.0 mL of ammonia solution were infused into 
the mixed solution every 15 minutes for four times. The 
obtained solutions were cooled to air temperature and 
dialyzed (MW=10000) for 72 hours in ultrapure water to 
remove unreacted raw materials. The PAA-Fe3O4 nanopar-
ticles were stored at 4℃ for use.
Conjugation	of	CSO	to	PAA-Fe3O4 nanoparticles
The carboxyl groups of PAA-Fe3O4 were first activated 
by EDC. In details, 200 mg EDC and 10 mL amount of 
PAA-Fe3O4 solution was magnetically stirred at indoor 
temperature for 15 min. Then, 1 g CSO, and 100 mg 
NHS were added to the mixed solution and reacted at 
37°C for two hours. The obtained solutions were dialyzed 
(MW=3000) for 48 hours in ultrapure water. The obtained 
CSO-PAA-Fe3O4 solution was stored at 4℃ before use.
Charaterization	 of	PAA-Fe3O4 nanoparticles 
andCSO-PAA-Fe3O4	nanoprobes
The transmission electron microscopy (TEM) imag-
es, fourier transform infrared (FTIR) spectra and surface 
zeta potential as well as the hydrodynamic diameters of 
fabricated nanoprobe were determined. For TEM charac-
terization, 10 μL amount of PAA-Fe3O4 andCSO-PAA-Fe-
3O4solution was dropped onto carbon-coated copper grids, 
respectively. After dried, copper grids were ready for TEM 
observation and photography. For FTIR scanning, dried 
PAA-Fe3O4 and CSO-PAA-Fe3O4 powders were dispersed 
in potassium bromide (KBr) powder to prepare tablets. 
The TENSOR27 Fourier transform infrared spectrometer 
was used for scanning in the range of 500-2000 cm-1. To 
analyze the surface zeta potential, 1 mL of PAA-Fe3O4 and 
CSO-PAA-Fe3O4 solution was placed into the sample cell 
and analyzed by the Zetasizer Nano ZS90 nanoparticle 
potential analyzer, respectively. 
Determination	of	iron	concentration
The concentration of iron ions was tested by inductive-
ly coupled plasma-mass spectrometry (ICP-MS)(Optima 
5300DV, PerkinElmer, USA). 50 μL of PAA-Fe3O4 and 
CSO-PAA-Fe3O4 solutions were mixed with 50 μL of con-
centrated nitric acid and placed in an oven at 80℃ for 30 
min, respectively. Then, 350 μL of 5% dilute nitric acid 
and 1.6 mL of H2O were added to determine iron ion con-
centration by ICP. 
T1	 relaxivity	determinations	of	PAA-Fe3O4 and 
CSO-PAA-Fe3O4
The T1 relaxation time of PAA-Fe3O4 (0.066, 0.133, 
0.266, 0.399, 0.532 mmol/L) and CSO-PAA-Fe3O4 (0.253, 
0.337, 0.422, 0.506, 0.675 mmol/L) at different iron ion 
concentrations were measured by MR scanning. The scan-
ning parameters were settled as follows. For T1WI, TR 
425 ms, TE 14.0 ms, reversal time 200~800 ms, matrix 
384 × 224, field of view (FOV) 18 × 18 cm, layer thick-
ness 3.0 mm, layer distance 1.5 mm. The original T1-map 
image was processed by GE Aw4.2 workstation to obtain 
the T1 relaxation time. The corresponding linear regression 
equations were plotted using the iron ion concentration as 
horizontal coordinates and the reciprocal of the samples’ 
T1 relaxation time at different concentrations as ordinate 
to calculate the T1 relaxation rates.
In	vitrocell	viability
RAW264.7 cells at logarithmic growth stage were inoc-
ulated in two 96-well plates at a concentration of 2 × 104 
cells/mL, followed by incubating at 37℃ for 24 hours. PAA-
Fe3O4 or CSO-PAA-Fe3O4 with different concentrations of 
Fe3+ (0, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, and 0.5 
mmol/L) were incubated with RAW264.7 cells for 24 hours, 
respectively. After discarding the nanomaterials and washing 
the cells in 96-well plates with PBS for three times, a 100 μL 
of 5 mg/mL MTT solution was injectedinto each well and 
placed at 37 ℃ for four hours. Finally, 100 μL of dimethyl 
sulfoxide (DMSO) was added to dissolve the purple crystals, 
and the absorbance value of each well was measured at 490 




6 mL of oil red O solution was diluted to 10 mL in a 
tube. After standing for 10 min, it was filtered in the dark. 
60 μg/mL ox-LDL pretreated RAW264.7 cells were treat-
ed with PAA-Fe3O4 or CSO-PAA-Fe3O4 (Fe
3+ concentra-
tion: 0, 0.15, 0.25, and 0.35 mmol/L) for 48 hours. After 
fixed with 4% paraformaldehyde for 15 min and rinsed 
twice with PBS, 500 μL oil red O working solution was 
added to each well. Dye in the dark for 40 min, and rinse 
with distilled water twice. The 24-well plates were the 
placed under an inverted fluorescence microscope (LEI-
CA) for observation. The obtained images were further 
analyzed using ImageJ software.
DOI: https://doi.org/10.30564/jams.v4i2.3039
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Effect	of	CSO-PAA-Fe3O4 on	 the	 inhibition	of	
macrophage	foaming	byTC	determination
60 μg/mL ox-LDL pretreated RAW264.7 cells were 
treated with PAA-Fe3O4 or CSO-PAA-Fe3O4 (Fe
3+ concen-
tration of 0, 0.15, 0.25, and 0.35 mmol/L) for 48 hours. 
The TC amount in RAW264.7 cells were determined fol-
lowing the Total Cholesterol Assay kit instructions. Brief-
ly, 400~500 million cells were collected and centrifuged 
at 1000 rpm for 20 min. After discarding the supernatant, 
1 mL of isopropanol was added and the cells were ultra-
sonic crushed for 1 min (intensity 20%, ultrasonic 2 s, 
stop 1 s). Then, the supernatant after centrifugation was 
collected as TC liquid to be tested. For TC detection, 50 
μL TC standard, 50 μL TC sample solution, and 150 μL 
TC working solution were added into 96-well plate. After 
standing for 24 hours, the absorbance value was measured 
at 500 nm by the microplate analyzer. The OD value of 
each well was measured and the TC content in the cells 
was calculated according to the formula:
TC (μmol/104 cells) = C (standard solution) × OD (assay 
tube) / OD (standard tube) / cell volume (104 cells)
C (standard liquid) = 0.5 μmol/mL
In	vitro	specific	MRI
RAW264.7 cells were incubated with PAA-Fe3O4 or 
CSO-PAA-Fe3O4 with different Fe
3+ concentrations of 
0, 0.25, and 0.35 mmol/L at 37 ℃ for two hours. After 
washed twice with PBS, trypsinized with EDTA-trypsin, 
and then suspended in 1% sepharose for MRI scanning. 
GE Signa 3.0 T whole-body magnetic resonance imager 
and a small animal coil were used for T1WI scanning. 
Statistical	analysis
Statistical analysis was performed using SPSS software 
(version 24.0), and data conforming to a normal distribu-
tion are denoted by`X ± S. Independent samples t-test was 
used for comparison between two groups, and one-fac-
tor ANOVA was used for comparison between multiple 
groups when the obtained data were by a normal distri-
bution; otherwise, Welch ANOVA test was used. If results 
were statistically significant, differences were analyzed by 
the LSD method or Dunnett’s T3 test. It was used to indi-
cate that the difference was statistically significant when 




PAA was combined with Fe3O4 nanoparticles, and then 
CSO was linked through amide bonds to prepare CSO-
PAA-Fe3O4 nanoprobes. Learnt from Figure 2a1 and 2b1, 
PAA-Fe3O4 and CSO-PAA-Fe3O4 were spherically shaped 
and uniform in size. Both nanoparticles showed good dis-
persion properties, no adhesion, and exhibited a significant 
increase in particle size from 5.93nm to 8.15nm after the 
modification of CSO (Figure 2a2 and 2b2). The zeta poten-
tials were also changed with such modification from -31.7 
mV for PAA-Fe3O4 to 25.13 mV forCSO-PAA-Fe3O4 (Fig-
ure 2a3 and 2b3). In addition, the average hydrodynamic 
diameter of PAA-Fe3O4 was increased from 95.64 nm to 
248.03 nm for CSO-PAA-Fe3O4 (Figure 2a4 and 2b4). The 
T1 relaxation times of PAA-Fe3O4 and CSO-PAA-Fe3O4 
at different concentrations were statistically significant-
ly different (F=1311.83, P<0.05; F=1357.21, P<0.05). 
From the data in Figure 2a5 and 2b5, it is apparent that the 
T1 relaxation time of PAA-Fe3O4 and CSO-PAA-Fe3O4 
decreased significantly with the increase of iron ions con-
centration. And the r1 relaxation rates of PAA-Fe3O4 and 
CSO-PAA-Fe3O4 were calculated to be 5.317 m and 6.147 
mM -1s-1, respectively. Both of the r1 relaxation rates are 
better than that of Gd-DTPA, commonly used in clinic, 
showing their possibility as MRI contrast agent. As Figure 
2 c shows, the FTIR spectra further testified the successful 
modification of CSO onto PAA-Fe3O4 nanoparticles. As 
shown in Figure 2c, the stretching vibration of C-N bond 
and tertiary alcohol C-O bond with the absorption peaks 
at 1321 cm-1 and 1155 cm-1 were observed on CSO-PAA-
Fe3O4 
[26]. A prominent absorption peak at 1073 cm-1 com-
ing from the stretching vibration absorption peak of C-O 
bond in the C-O-C structure on the CSO ring could also 
be detected, showing the existence of CSO in CSO-PAA-
Fe3O4. All of the above changes indicated the successful 
fabrication of CSO-PAA-Fe3O4 nanoprobes.
Cytotoxicity	assessment	of	PAA-Fe3O4	and	CSO-
PAA-Fe3O4
The biocompatibility of PAA-Fe3O4 and CSO-PAA-
Fe3O4 were assessed by MTT assay. As showed in Figure 
3, there were no significant differences in the absorbance 
values of RAW264.7 cells neither treated with PAA-
Fe3O4 nanoparticles, or with CSO-PAA-Fe3O4 ranging 
from 0.05~0.50 mmol/L Fe (F=2.138, P>0.05; F=1.904, 
P>0.05), indicating no significant cytotoxic influence of 
PAA-Fe3O4 and CSO-PAA-Fe3O4 on RAW264.7 cell pro-
liferation and desirable biocompatibility.
Oil	red	O	staining	to	detect	the	lipidalaggregation	
in	RAW264.7	cells
To show the influence of our fabricated CSO-PAA-
DOI: https://doi.org/10.30564/jams.v4i2.3039
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Figure	2. Characterizations of PAA-Fe3O4 (a) and CSO-PAA-Fe3O4 (b). (1-4) TEM observations, particle size distribu-
tion, Zeta surface potential distribution, and hydrodynamic diameters of PAA-Fe3O4 and CSO-PAA-Fe3O4. T1-weighted 
phantom images of PAA-Fe3O4 and CSO-PAA-Fe3O4 at different Fe
3+ concentrationsand the relaxation rate fit of PAA-
Fe3O4 and CSO-PAA-Fe3O4 (5). Fourier transform infrared absorption spectra of PAA-Fe3O4 and CSO-PAA-Fe3O4 (c).
DOI: https://doi.org/10.30564/jams.v4i2.3039
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Fe3O4 nanoprobes on the lipidal accumulation of 
RAW264.7 cells, 8 groups were set as follows. RAW264.7 
cells without any treatment were designated as the blank 
control group (BLK), and RAW264.7 cells pretreated 
with 60 μg/mL ox-LDL was set as the model group (NC). 
RAW264.7 cells pretreated with 60 μg/mL ox-LDL first, 
and then incubated with different concentrations of PAA-
Fe3O4 or CSO-PAA-Fe3O4 were used as experimental 
groups. As illustrated in Figure 4, compared with the BLK 
group, the amount of the intracellular lipid accumulation 
was significantly increased in NC group. And no obvious 
change of intracellular lipid accumulation between the 
PAA-Fe3O4groups and the NC group, showing the little ef-
fect of PAA-Fe3O4 on the inhibition of lipid accumulation 
in RAW264.7 cells. But when compared the PAA-Fe3O4 
and CSO-PAA-Fe3O4 groups, the difference was signif-
Figure	3. Cytotoxicity assessment of PAA-Fe3O4 and CSO-PAA-Fe3O4 against RAW264.7 (n=6).
DOI: https://doi.org/10.30564/jams.v4i2.3039
Figure	4. The RAW264.7 cells were stained with oil red O, and the intracellular lipids were stained red. No significant 
lipid accumulation was observed in the blank control group (a), but significant lipidalaggregation in the model group 
was shown (b). In PAA-Fe3O4 groups, the lipidalaggregation was unchanged when the iron ion concentration increased 
(0.15, 0.25 and 0.35mmol/L) (c-e). The lipid accumulation gradually decreased with the increase of iron ion concentra-
tion in CSO-PAA-Fe3O4 groups (0.15, 0.25 and 0.35mmol/L) (f-h).
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icant and a significant decrease in the intracellular lipid 
accumulation with a gradual increase of CSO-PAA-Fe3O4. 
Analysis using ImageJ software further presented such 
difference semi-quantitatively. The amount of intracellu-
lar lipid accumulation in the NC group was significantly 
higher than that in the BLK group (F=83.108, P<0.05). 
But there was no significant difference in the level of lipid 
accumulation between the NC group and the PAA-Fe3O4 
groups (F=0.694, P>0.05) and CSO-PAA-Fe3O4 group 
with a Fe3+ concentration of 0.15 mmol/L (F=12.353, 
P>0.05). However, significant differences existed between 
the NC group and CSO-PAA-Fe3O4 groups with Fe
3+ con-
centratinos of 0.25 and 0.35 mmol/L (F=15.983, P<0.05) 
as well as between CSO-PAA-Fe3O4 groups (F=98.076, 
P<0.05). Such phenomena might come from the existence 
of CSO and the different amount of CSO in CSO-PAA-
Fe3O4 nanoprobes. 
Figure	5. ImageJ analysis of the staining area of 
RAW264.7 cells by Oil Red O. BLK: Blank group; NC: 
Model group; #: P level less than 0.05 compared with the 




The absorbance values of RAW264.7 cells induced 
by 60 μg/mL ox-LDL with or without further incubation 
with PAA-Fe3O4 or CSO-PAA-Fe3O4 at different iron 
concentrations were determined. It was clearly displayed 
that compared with the BLK group, there was a remarka-
ble increase in the content of TC in NC group(F=35.910, 
P<0.05). No statistically significant difference of the TC 
contents in RAW264.7 cells after incubation with PAA-
Fe3O4 solutions of different iron concentrations (F=3.306, 
P>0.05). It presented a significant gradual decreasing 
trend of TC content in cells after incubated with increas-
ing iron ion concentrations of CSO-PAA-Fe3O4 (F=35.128, 
P<0.05). In Figure 6B, there was noteworthy that CSO-
PAA-Fe3O4 with 0.15 mmol/L Fe
3+ did not produce a sig-
nificant difference in the  TC content between the CSO-
PAA-Fe3O4 and NC groups, which is consistent with the 
results of the previous analysis of the intracellular lipid 
accumulation content. The difference in the content of TC 
in the CSO-PAA-Fe3O4 group at different concentrations 
was statistically significant (P<0.05). CSO-PAA-Fe3O4 
with 0.25 mmol/L and 0.35 mmol/L Fe3+ down-regulated 
the content of TC in RAW264.7 cells to 62.6% and 56.5%, 
respectively.
Figure	6. TC concentrations in RAW264.7 cells incubat-
ed with different concentration ranges of PAA-Fe3O4 (a) 
and CSO-PAA-Fe3O4 (b). BLK: blank group; NC: model 
group; #: P level less than 0.05 compared with the mod-
el group; *: P level less than0.05 by paired comparison 
(n=6).
Specific	MRI	of	RAW264.7	cells	in	vitro
As Figure 7 showed, there was a significant difference 
in T1 relaxation time between the blank and experimental 
groups shown by T1-map color plots. In the Fe
3+ concen-
tration of 0.25 mmol/L, the T1 relaxation times of PAA-
DOI: https://doi.org/10.30564/jams.v4i2.3039
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Fe3O4 and CSO-PAA-Fe3O4 group were (800.6 ± 14.30) 
ms and (647.2 ± 21.91) ms, and the T1 relaxation time of 
the PAA-Fe3O4 group was significantly longer than that 
of the CSO-PAA-Fe3O4 group. One-factor ANOVA anal-
ysis compared the T1 relaxation times of the BLK group, 
0.25 mmol/L iron ion concentration of PAA-Fe3O4 group, 
and CSO-PAA-Fe3O4 group, and the differences were 
statistically significant (F=2418.877, P<0.05). Addition-
ally, the T1 relaxation times of CSO-PAA-Fe3O4 treated 
cells decreased with the increase of Fe3+ concentration 
(0.15 mmol/L, 0.25 mmol/L, and 0.35 mmol/L), which 
were (739.4 ± 31.59) ms, (647.2 ± 21.91) ms, and (565.9 
± 26.38) ms, respectively. The results showed that there 
were statistical differences in T1 relaxation time between 
the BLK group and CSO-PAA-Fe3O4 group for each Fe
3+ 
concentration (F=2310.838, P<0.05). The above MR 
imaging results showed that the cellular binding amount 
of CSO-PAA-Fe3O4 was significantly higher than that of 
PAA-Fe3O4at the same Fe
3+ concentration, and the cellular 
binding amount of CSO-PAA-Fe3O4 increased with the in-
crease of nanoprobes. CSO-PAA-Fe3O4 nanoprobes could 
target RAW264.7 cells and might come from the specific 
binding of CSO to the mannose receptor of RAW264.7 
cells and the endocytosis to achieve the targeted MRI of 
RAW264.7 cells.
4. Conclusions
In conclusion, targeted MRI and therapeutic nanoprobe 
based on CSO-PAA-Fe3O4 was successfully designed and 
was successfully developed. In the process of ox-LDL 
induction of macrophages, these nanoprobes could effec-
tively enter the interior of macrophages and effectively 
inhibit the transformation of macrophages into foam cells. 
CSO-PAA-Fe3O4 exhibited good T1-weighted macrophage 
targeting MRI capability and a high therapeutic effect on 
the inhibition of foamy macrophages formation. 
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